Clinical Trial Update: Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating trilaciclib in combination with FOLFOXIRI and bevacizumab for metastatic colorectal cancer was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bevacizumab (bevacizumab)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)
• trilaciclib (trilaciclib)

Snippet

Sponsor: G1 Therapeutics, Inc. | Conditions: Colorectal Cancer Metastatic, Myelosuppression-Adult | Phase 3 | Status: TERMINATED | Results posted: 2024-11-26